DATA GRAPHICS | Product Development
Vulnerability of COVID-19 mAbs to emerging variants: Data Byte
Lilly’s mAbs hit hardest, while a Vir mAb that was designed to work across coronavirus species ranks among the least affected
January 28, 2021 2:47 AM UTC
Data on the vulnerability of mAbs to emerging SARS-CoV-2 variants supports the hypothesis that antibodies that bind epitopes conserved across coronavirus species will be most resilient to mutations.
Recent studies on neutralizing mAb potencies against emerging variants suggest that products from Vir Biotechnology Inc. (NASDAQ:VIR) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are among the least vulnerable to the mutants, while mAbs from Eli Lilly and Co. (NYSE:LLY) and its partners are the most likely to lose efficacy. ...
BCIQ Company Profiles
BCIQ Target Profiles